Jazz Pharmaceuticals plc — Director's Dealing 2023

Jun 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-06-05

Reporting Person: Sablich Kim (EVP, GM of U.S.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-05	Ordinary Shares	D	2082	$129.73	Disposed	28478	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.